does retatrutide give you heartburn and Heartburn: Evidence, Side Effects, and Management – Bolt Pharmacy A Potential Breakthrough in Weight

Little is known about the association of discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) with outcomes in patients with CKD

Multiple Endocrine Neoplasia Type 2 is a rare inherited condition that predisposes individuals to develop certain endocrine tumors, including medullary thyroid carcinoma (mentioned above)

Some clinical trials have been conducted on the repurposing of pioglitazone for PD treatment

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors, giving it a broader metabolic mechanism than single- or dual-pathway therapies

While standard GLP-1 medications, like Ozempic, are usually covered by insurance for diabetes or weight loss, insurance rarely covers off-label or compounded formulations